TP53 DNA Binding Domain Mutations Predict Progression-Free Survival of Bevacizumab Therapy in Metastatic Colorectal Cancer

(1) Background: Bevacizumab-based regimens are a standard treatment for metastatic colorectal cancer (mCRC) patients, however meaningful clinical biomarkers for treatment benefit remain scarce. (2) Methods: Tumor samples from 36 mCRC patients treated with bevacizumab-based chemotherapy underwent com...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Hung-Chih, You, Jeng-Fu, Chen, Shu-Jen, Chen, Hua-Chien, Yeh, Chien-Yuh, Tsai, Wen-Sy, Hung, Hsin-Yuan, Yang, Tsai-Sheng, Lapke, Nina, Tan, Kien Thiam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721375/
https://www.ncbi.nlm.nih.gov/pubmed/31366114
http://dx.doi.org/10.3390/cancers11081079

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721375/
https://www.ncbi.nlm.nih.gov/pubmed/31366114
http://dx.doi.org/10.3390/cancers11081079

Ejemplares similares